Eyoca is developing a disposable device for the treatment of Chronic Total Occlusion.
Maayan Ventures Ltd. (TASE:MAYN) has announced that it has obtained permission from the Office of the Chief Scientist to operate Eyoca Medical Ltd. at its incubator. Eyoca is developing a disposable device for the treatment of Chronic Total Occlusion. Maayan will invest NSI 2.7 million in Eyoca for 35% of its shares.
Eyoca’s device is designed to open blockages in cardiac arteries without bypass surgery. The product is a kind of drill built into a conductive wire that is inserted into a cardiac artery via the vascular system in a non-invasive manner, simila to a catheter.
Published by Globes [online], Israel business news - www.globes.co.il - on June 14, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006